NASDAQ:ZBIO Zenas Biopharma (ZBIO) Stock Price, News & Analysis $11.92 +0.36 (+3.11%) As of 05/2/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Zenas Biopharma Stock (NASDAQ:ZBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zenas Biopharma alerts:Sign Up Key Stats Today's Range$11.53▼$12.4150-Day Range N/A52-Week Range$5.83▼$26.25Volume111,593 shsAverage Volume192,177 shsMarket Capitalization$498.66 millionP/E RatioN/ADividend YieldN/APrice Target$40.00Consensus RatingBuy Company OverviewZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.Read More… Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zenas Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ZBIO Stock News HeadlinesZenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights – ZBIOMay 2 at 2:08 PM | globenewswire.comShareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIOMay 2 at 5:45 AM | prnewswire.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 4, 2025 | Golden Portfolio (Ad)Cohen Milstein Seeks Investors to Lead Suit to Hold Zenas BioPharma (ZBIO) Accountable for IPO-Related FraudMay 1 at 3:08 PM | globenewswire.comThe Gross Law Firm Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 – ZBIOMay 1 at 12:54 PM | globenewswire.comThe Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming DeadlineMay 1 at 5:45 AM | prnewswire.comZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 30, 2025 | globenewswire.comRobbins LLP Reminds ZBIO Stockholders with Large Losses to Contact the Law Firm for Information on Leading the Zenas BioPharma, Inc. Class ActionApril 29, 2025 | globenewswire.comSee More Headlines ZBIO Stock Analysis - Frequently Asked Questions How have ZBIO shares performed this year? Zenas Biopharma's stock was trading at $7.90 at the beginning of the year. Since then, ZBIO shares have increased by 50.9% and is now trading at $11.92. View the best growth stocks for 2025 here. When did Zenas Biopharma IPO? Zenas Biopharma (ZBIO) raised $225 million in an IPO on Friday, September 13th 2024. The company issued 13,235,294 shares at a price of $17.00 per share. When did Zenas Biopharma's lock-up period expire? Zenas Biopharma's lock-up period expired on Wednesday, March 12th. Zenas Biopharma had issued 13,235,294 shares in its public offering on September 13th. The total size of the offering was $224,999,998 based on an initial share price of $17.00. Since the end of Zenas Biopharma's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are Zenas Biopharma's major shareholders? Zenas Biopharma's top institutional investors include Alps Advisors Inc. (0.07%), Rhumbline Advisers (0.03%) and New York State Common Retirement Fund (0.01%). How do I buy shares of Zenas Biopharma? Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zenas Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas Biopharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZBIO Previous SymbolNASDAQ:ZBIO CIK1953926 WebN/A Phone(857) 271-2954FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$40.00 High Stock Price Target$45.00 Low Stock Price Target$35.00 Potential Upside/Downside+235.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$5 million Price / Sales99.73 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares41,834,000Free FloatN/AMarket Cap$498.66 million OptionableN/A BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.